These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 37449302)

  • 1. Transarterial chemoembolization for hepatocellular carcinoma: 2023 expert consensus-based practical recommendations of the Korean Liver Cancer Association.
    Cho Y; Choi JW; Kwon H; Kim KY; Lee BC; Chu HH; Lee DH; Lee HA; Kim GM; Oh JS; Hyun D; Lee IJ; Rhim H;
    J Liver Cancer; 2023 Sep; 23(2):241-261. PubMed ID: 37449302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transarterial chemoembolization for hepatocellular carcinoma: 2023 Expert consensus-based practical recommendations of the Korean Liver Cancer Association.
    Cho Y; Choi JW; Kwon H; Kim KY; Lee BC; Chu HH; Lee DH; Lee HA; Kim GM; Oh JS; Hyun D; Lee IJ; Rhim H;
    Clin Mol Hepatol; 2023 Jul; 29(3):521-541. PubMed ID: 37482892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transarterial Chemoembolization for Hepatocellular Carcinoma: 2023 Expert Consensus-Based Practical Recommendations of the Korean Liver Cancer Association.
    Cho Y; Choi JW; Kwon H; Kim KY; Lee BC; Chu HH; Lee DH; Lee HA; Kim GM; Oh JS; Hyun D; Lee IJ; Rhim H;
    Korean J Radiol; 2023 Jul; 24(7):606-625. PubMed ID: 37404104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Liver Tumors with Lipiodol TACE: Technical Recommendations from Experts Opinion.
    de Baere T; Arai Y; Lencioni R; Geschwind JF; Rilling W; Salem R; Matsui O; Soulen MC
    Cardiovasc Intervent Radiol; 2016 Mar; 39(3):334-43. PubMed ID: 26390875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transarterial chemoembolization with drug-eluting beads in hepatocellular carcinoma.
    Nam HC; Jang B; Song MJ
    World J Gastroenterol; 2016 Oct; 22(40):8853-8861. PubMed ID: 27833376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transarterial chemoembolization using drug eluting beads for the treatment of hepatocellular carcinoma: Now and future.
    Woo HY; Heo J
    Clin Mol Hepatol; 2015 Dec; 21(4):344-8. PubMed ID: 26770921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma: a short-term efficacy and safety study.
    Wu B; Zhou J; Ling G; Zhu D; Long Q
    World J Surg Oncol; 2018 Mar; 16(1):69. PubMed ID: 29587773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical practice of transarterial chemoembolization for hepatocellular carcinoma: consensus statement from an international expert panel of International Society of Multidisciplinary Interventional Oncology (ISMIO).
    Lu J; Zhao M; Arai Y; Zhong BY; Zhu HD; Qi XL; de Baere T; Pua U; Yoon HK; Madoff DC; Teng GJ;
    Hepatobiliary Surg Nutr; 2021 Oct; 10(5):661-671. PubMed ID: 34760969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conventional versus drug-eluting bead transarterial chemoembolization: A better option for treatment of unresectable hepatocellular carcinoma.
    Razi M; Jianping G; Xu H; Ahmed MJ
    J Interv Med; 2021 Feb; 4(1):11-14. PubMed ID: 34805941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multidisciplinary Taiwan Consensus Recommendations for the Use of DEBDOX-TACE in Hepatocellular Carcinoma Treatment.
    Chang PY; Huang CC; Hung CH; Yu CY; Wu DK; Hwang JI; Liang PC; Wu RH; Tsai WL; Lin YJ; Liu YS; Liang HL; Lee RC; Chen CH
    Liver Cancer; 2018 Oct; 7(4):312-322. PubMed ID: 30488021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the Treatment Response of Drug-Eluting Bead Transarterial Chemoembolization and Conventional Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma.
    Adel H; Shazlee MK; Qamar S; Hyder SMS; Razaque A
    Cureus; 2023 Jul; 15(7):e41701. PubMed ID: 37575777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of Drug-Eluting Beads Transarterial Chemoembolization Plus Camrelizumab Compared With Conventional Transarterial Chemoembolization Plus Camrelizumab for Unresectable Hepatocellular Carcinoma.
    Ren Y; Guo Y; Chen L; Sun T; Zhang W; Sun B; Zhu L; Xiong F; Zheng C
    Cancer Control; 2022; 29():10732748221076806. PubMed ID: 35343254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The position of transarterial chemoembolization with drug-eluting beads and yttrium-90 transarterial radioembolization in patients with hepatocellular carcinoma: Consensus statements from a Delphi-method expert panel in Turkey.
    Akarca US; Akhan O; Bilgiç S; Bozkurt MF; Cantaşdemir M; Çermik TF; Çakaloğlu Y; Er Ö; Ilgıt E; Çapa Kaya G; Küçük NÖ; Numan F; Parıldar M; Türkmen C
    Diagn Interv Radiol; 2021 Nov; 27(6):732-739. PubMed ID: 34792027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of initial tumor responses to transarterial bland embolization and drug-eluting beads-transarterial chemoembolization in the management of hepatocellular carcinoma: a propensity-score matching analysis.
    Guo J; Wang W; Zhang Y; Xu L; Kong J
    J Gastrointest Oncol; 2021 Aug; 12(4):1838-1850. PubMed ID: 34532132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transarterial chemoembolization using gelatin sponges or microspheres plus lipiodol-doxorubicin versus doxorubicin-loaded beads for the treatment of hepatocellular carcinoma.
    Liu YS; Ou MC; Tsai YS; Lin XZ; Wang CK; Tsai HM; Chuang MT
    Korean J Radiol; 2015; 16(1):125-32. PubMed ID: 25598680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of raltitrexed-eluting CalliSpheres
    Sun Z; Jiao D; Fang Y; Liu Y; Xu K; Zhang C; Huang Y; Han X
    Ther Adv Med Oncol; 2024; 16():17588359241229661. PubMed ID: 38362379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conventional
    Song JE; Kim DY
    World J Hepatol; 2017 Jun; 9(18):808-814. PubMed ID: 28706579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transarterial therapies in patients with hepatocellular carcinoma eligible for transarterial embolization: a US cost-effectiveness analysis.
    Patel MV; Davies H; Williams AO; Bromilow T; Baker H; Mealing S; Holmes H; Anderson N; Ahmed O
    J Med Econ; 2023; 26(1):1061-1071. PubMed ID: 37632520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma.
    Kloeckner R; Weinmann A; Prinz F; Pinto dos Santos D; Ruckes C; Dueber C; Pitton MB
    BMC Cancer; 2015 Jun; 15():465. PubMed ID: 26059447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment efficacy and safety of drug-eluting beads transarterial chemoembolization versus conventional transarterial chemoembolization in hepatocellular carcinoma patients with arterioportal fistula.
    Cai L; Li H; Guo J; Zhao W; Duan Y; Hou X; Cheng L; Du H; Shao X; Diao Z; Hao Y; Zheng X; Li C; Li W
    Cancer Biol Ther; 2022 Dec; 23(1):89-95. PubMed ID: 35230928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.